Outcomes of patients with differentiated thyroid carcinoma following initial therapy

Thyroid

Volumn 16, Issue 12, 2006, Pages 1229-1242

  Jonklaas, Jacqueline ^a   Sarlis, Nicholas J ^a,m   Litofsky, Danielle ^b   Ain, Kenneth B ^c   Bigos, S Thomas ^d   Brierley, James D ^e   Cooper, David S ^f   Haugen, Bryan R ^g   Ladenson, Paul W ^h   Magner, James ⁱ   Robbins, Jacob ^j   Ross, Douglas S ^k   Skarulis, Monica ^j   Maxon, Harry R ^l   Sherman, Steven I ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^d MAINE MEDICAL CENTER   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f SINAI HOSPITAL OF BALTIMORE   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ GENZYME CORPORATION   (United States)

^j NATIONAL INSTITUTES OF HEALTH   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^m SANOFI   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ADULT; AGED; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; THYROID CARCINOMA; THYROIDECTOMY; TUMOR DIFFERENTIATION;

ADENOCARCINOMA, FOLLICULAR; ADULT; ANTITHYROID AGENTS; CARCINOMA, PAPILLARY; COHORT STUDIES; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; REGISTRIES; RISK; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 33845444316     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.16.1229     Document Type: Conference Paper

References (61)

1. Jemal A, Murray T, Ward E, et al. 2005 Cancer statistics, 2005. CA Cancer J Clin 55:10-30.
2. Mazzaferri EL 2006 Managing small thyroid cancers. JAMA 295:2179-2182.
3. Sherman SI, Brierley JD, Sperling M, et al. 1998 Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83:1012-1021.
4. Udelsman R, Lakatos E, Ladenson P 1996 Optimal surgery for papillary thyroid carcinoma. World J Surg 20:88-93.
5. Hundahl SA, Cady B, Cunningham MP, et al. 2000 Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 89:202-217.
6. Spencer CA, Takeuchi M, Kazarosyan M, et al. 1998 Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 83:1121-1127.
7. Massin JP, Savoie JC, Garnier H, Guiraudon G, Leger FA, Bacourt F 1984 Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer 53:982-992.
8. Miccoli P, Antonelli A, Spinelli C, Ferdeghini M, Fallahi P, Baschieri L 1998 Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident. Arch Surg 133:89-93.
9. Wartofsky L, Sherman SI, Gopal J, Schlumberger M, Hay ID 1998 The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 83: 4195-4203.
10. DeGroot LJ, Kaplan EL, Straus FH, Shukla MS 1994 Does the method of management of papillary thyroid carcinoma make a difference in outcome? World J Surg 18:123-130.
11. Sanders LE, Rossi RL 1995 Occult well differentiated thyroid carcinoma presenting as cervical node disease. World J Surg 19:642-646; discussion 646-647.
12. Wanebo H, Coburn M, Teates D, Cole B 1998 Total thyroidectomy does not enhance disease control or survival even in high-risk patients with differentiated thyroid cancer. Ann Surg 227:912-921.
13. Haigh PI, Urbach DR, Rotstein LE 2005 Extent of thyroidectomy is not a major determinant of survival in low-or high-risk papillary thyroid cancer. Ann Surg Oncol 12: 81-89.
14. Mazzaferri EL, Kloos RT 2001 Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447-1463.
15. Mazzaferri EL 1997 Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 7:265-271.
16. Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB 1998 The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 82:375-388.
17. Chow SM, Law SC, Mendenhall WM, et al. 2002 Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys 52:784-795.
18. Samaan NA, Schultz PN, Hickey RC, et al. 1992 The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 75:714-720.
19. Krishnamurthy GT, Blahd WH 1977 Radioiodine I-31 therapy in the management of thyroid cancer. A prospective study. Cancer 40:195-202.
20. Petrich T, Widjaja A, Musholt TJ, et al. 2001 Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age. Eur J Nucl Med 28:203-208.
21. Lerch H, Schober O, Kuwert T, Saur HB 1997 Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol 15:2067-2075.
22. Taylor T, Specker B, Robbins J, et al. 1998 Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 129:622-627.
23. Shoup M, Stojadinovic A, Nissan A, et al. 2003 Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 197:191-197.
24. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC 2004 Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89:3668-3676.
25. Durante C, Haddy N, Baudin E, et al. 2006 Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
26. Hay ID, Thompson GB, Grant CS, et al. 2002 Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26:879-885.
27. Derwahl M, Broecker M, Kraiem Z 1999 Clinical review 101: thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors. J Clin Endocrinol Metab 84:829-834.
28. Hoelting T, Tezelman S, Siperstein AE, Duh QY, Clark OH 1995 Biphasic effects of thyrotropin on invasion and growth of papillary and follicular thyroid cancer in vitro. Thyroid 5:35-40.
29. Tanaka K, Fukunari N, Nagahama M, Sugino K, Ito K, Shimizu K 2003 Long term effect of TSH suppression therapy on papillary carcinoma with distant metastases. 75th Annual Meeting of the American Thyroid Association. Abstract 132.
30. Balme H 1954 Metastatic carcinoma of the thyroid successfully treated with thyroxine. Lancet 1:812-813.
31. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428.
32. Staunton MD 1994 Thyroid cancer: a multivariate analysis on influence of treatment on long-term survival. Eur J Surg Oncol 20:613-621.
33. Young RL, Mazzaferri EL, Rahe AJ, Dorfman SG 1980 Pure follicular thyroid carcinoma: impact of therapy in 214 patients. J Nucl Med 21:733-737.
34. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB 1988 Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 14:1063-1075.
35. Cunningham MP, Duda RB, Recant W, Chmiel JS, Sylvester JA, Fremgen A 1990 Survival discriminants for differentiated thyroid cancer. Am J Surg 160:344-347.
36. Rossi RL, Cady B, Silverman ML, et al. 1988 Surgically incurable well-differentiated thyroid carcinoma. Prognostic factors and results of therapy. Arch Surg 123:569-574.
37. Sanders LE, Cady B 1998 Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 133:419-425.
38. Cooper DS, Specker B, Ho M, et al. 1998 Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8:737-744.
39. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C 1996 Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 81:4318-4323.
40. McGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F, Sarlis NJ 2002 Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 34:554-564.
41. Biondi B, Filetti S, Schlumberger M 2005 Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Prac Endocrinol Metab 1:32-38.
42. Fleming I, Cooper J, Henson D, Hutter R, Kennedy B, Murphy G (eds) 1997 American Joint Committee on Cancer Staging Manual. 5th ed. Lippincott-Raven, Philadelphia.
43. D'Agostino RB, Jr 1998 Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265-2281.
44. Rubin DB 1997 Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757-763.
45. Cooper DS, Doherty GM, Haugen BR, et al. 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-142.
46. Franc B, Valenty M, Galakhin K, et al. 2003 Histological validation of diagnoses of thyroid cancer among adults in the registries of Belarus and the Ukraine. Br J Cancer 89:2098-2103.
47. Hirokawa M, Carney JA, Goellner JR, et al. 2002 Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol 26:1508-1514.
48. Fassina AS, Montesco MC, Ninfo V, Denti P, Masarotto G 1993 Histological evaluation of thyroid carcinomas: reproducibility of the "WHO" classification. Tumori 79:314-320.
49. Lloyd RV, Erickson LA, Casey MB, et al. 2004 Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28:1336-1340.
50. LiVolsi VA, Asa SL 1994 The demise of follicular carcinoma of the thyroid gland. Thyroid 4:233-236.
51. Goldacre MJ 1993 Cause-specific mortality: understanding uncertain tips of the disease iceberg. J Epidemiol Community Health 47:491-496.
52. Ravakhah K 2006 Death certificates are not reliable: revivification of the autopsy. South Med J 99:728-733.
53. D'Amico M, Agozzino E, Biagino A, Simonetti A, Marinelli P 1999 III-defined and multiple causes on death certificates-a study of misclassification in mortality statistics. Eur J Epidemiol 15:141-148.
54. Chamberlain J, Coleman D, Ellman R, Moss S 1991 Verification of the cause of death in the trial of early detection of breast cancer. UK Trial of Early Detection of Breast Cancer Group. Trial Co-ordinating Centre. Br J Cancer 64:1151-1156.
55. Lambert V, Thierens H, Monsieurs M, Roncancio C, Laurent C 2001 Translocation frequencies measured in patients one year after radioactive iodine therapy for thyrotoxicosis. Int J Radiat Biol 77:679-685.
56. Gutierrez S, Carbonell E, Galofre P, Creus A, Marcos R 1999 Cytogenetic damage after 131-iodine treatment for hyperthyroidism and thyroid cancer. A study using the micronucleus test. Eur J Nucl Med 26:1589-1596.
57. Williams ED 1986 Relation between 131I therapy for thyrotoxicosis and development of thyroid carcinoma. Lancet 2(8504):456-457.
58. Sandeep TC, Strachan MW, Reynolds RM, et al. 2006 Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab 91:1819-1825.
59. Hay ID, McConahey WM, Goellner JR 2002 Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc 113:241-260.
60. Abel U, Wollermann C 2003 Methodological aspects of the evaluation of postoperative cancer surveillance. Part I: validity. Clin Lab 49:367-377.
61. Prorok PC 1992 Epidemiologic approach for cancer screening. Problems in design and analysis of trials. Am J Pediatr Hematol Oncol 14:117-128.